Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Why ResMed (RMD) is Poised to Beat Earnings Estimates Again

2026-04-20
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

2026-04-20
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT

2026-04-19
With strong revenue growth projections, ResMed Inc. (NYSE:RMD) secures a spot on our list of the best long-term ASX stocks to buy right now. On April 15, 2026, JPMorgan initiated coverage of ResMed Inc. (NYSE:RMD) with an “Overweight” rating and an A$37.60 price target, stating that the company remains well-positioned even as investor attention increasingly […]

1 of Wall Street’s Favorite Stock Worth Investigating and 2 Facing Headwinds

2026-04-17
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Should You Continue to Hold Resmed Stock in Your Portfolio?

2026-04-17
RMD's growth strategy, rising device demand and solid finances support momentum, but macro pressures and stiff competition could test its outlook.

ResMed Inc (NYSE:RMD): A Durable Dividend Growth Stock for Passive Income

2026-04-14
ResMed Inc. offers a sustainable dividend with a 10-year growth history, backed by strong profitability, a low payout ratio, and a rock-solid balance sheet for durable passive income.

Citigroup Maintains Buy on ResMed, Lowers Price Target to $340

2026-04-09
Citigroup analyst Laura Sutcliffe maintains ResMed (NYSE:RMD) with a Buy and lowers the price target from $345 to $340.

Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

2026-04-07
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Anesthesia and Respiratory Devices Market size & share revenue was valued at approximately USD 57.2 Billion in 2025 and is expected to reach USD 60.5 Billion in 2026 and is expected to reach around USD 100.5 Billion by 2035, at a CAGR of 5.8% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Medtronic, O2

Top 50 High-Quality Dividend Growth Stocks For April 2026

2026-04-07
I track a universe of 50 high-quality dividend growth stocks to identify attractive entry points based on updated valuations and forward return estimates.

I Shared 42 Sell Ratings In 2019. Here Is How They Have Performed Long-Term.

2026-04-07
Tested 42 S&P 500 “Sell” ratings with Full-Cycle Analysis: most underperformed SPY/RSP over 6–7 years, helping spot overvalued stocks.